Open AccessEfficacy of docetaxel combined carboplatin for the treatment of patients with castration-resistant prostate cancer
Author(s) -
Chun-Lin Pu,
Jiuzhi Li,
Wenlong Fan
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000020297
Subject(s) - medicine , docetaxel , carboplatin , prostate cancer , oncology , castration , cancer , urology , chemotherapy , gynecology , cisplatin , hormone
Background: A numerous published studies have reported that docetaxel combined carboplatin (DC) has been utilized for the treatment of patients with castration-resistant prostate cancer (CRPC). However, there are still contradictory results. Therefore, this systematic review and meta-analysis will explore the efficacy and safety of DC for the treatment of patients with CRPC. Methods: We will systematically and comprehensively search MEDLINE, EMBASE, Cochrane Library, Web of Science, CINAHL, WANGFANG, CBM, and CNKI from the beginning up to the March 1, 2020, regardless language and publication time. We will consider randomized controlled trials that evaluated the efficacy and safety of DC for the treatment of patients with CRPC. The treatment effects of all dichotomous data will be estimated as risk ratio and 95% confidence intervals (CIs), and that of continuous outcomes will be calculated as standardized mean difference or mean difference and 95% CIs. Methodological quality will be appraised by Cochrane risk of bias tool, and quality of evidence will be identified by Grading of Recommendations Assessment Development and Evaluation. Statistical analysis will be undertaken by RevMan 5.3 software. Results: This study will systematically explore the efficacy and safety of DC for the treatment of patients with CRPC. Conclusion: This study may provide helpful evidence to determine whether DC is an effective treatment for patients with CRPC or not. Systematic review registration: INPLASY202040076.